Active surveillance, radiofrequency ablation, or cryoablation for the nonsurgical management of a small renal mass: A cost-utility analysis

Annals of Surgical Oncology

Volumn 20, Issue 11, 2013, Pages 3675-3684

  Bhan, Sasha N ^a   Pautler, Stephen E ^b   Shayegan, Bobby ^c   Voss, Maurice D ^d   Goeree, Ron A ^a,e   You, John J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c Department of Surgery   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e Research Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLEEDING; COLON INJURY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CRYOABLATION; DISEASE COURSE; DISEASE SURVEILLANCE; FEMALE; HEALTH CARE COST; HEMATURIA; HUMAN; KIDNEY BIOPSY; KIDNEY TUMOR; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; RADIOFREQUENCY ABLATION; THERMAL INJURY; TUMOR VOLUME; URETER INJURY; URETER STRICTURE; URINARY TRACT FISTULA; URINARY TRACT OBSTRUCTION; URINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CATHETER ABLATION; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; KIDNEY NEOPLASMS; LIFE EXPECTANCY; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; NEOPLASM STAGING; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84883818201     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3028-0     Document Type: Article

References (54)

1. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98:1331-4.
2. You JJ, Purdy I, Rothwell DM, Przybysz R, Fang J, Laupacis A. Indications for and results of outpatient computed tomography and magnetic resonance imaging in Ontario. Can Assoc Radiol J. 2008;59:135-43.
3. Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. Cancer. 2004;100:738-45.
4. Canadian Kidney Cancer Forum, 2008. Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement. Can Urol Assoc J. 2008;2:175-82.
5. Statistics Canada. A portrait of seniors in Canada. http://www.statcan. gc.ca/ads-annonces/89-519-x/index-eng.htm (2007). Accessed 9 Aug 2010.
6. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006;175:425-31.
7. Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma - a meta-analysis and review. J Urol. 2008;179:1227-33.
8. Jewett MA, Zuniga A. Renal tumor natural history: the rationale and role for active surveillance. Urol Clin North Am. 2008;35:627-34.
9. Rendon RA. Active surveillance as the preferred management option for small renal masses. Can Urol Assoc J. 2010;4:136-8.
10. Carraway WA, Raman JD, Cadeddu JA. Current status of renal radiofrequency ablation. Curr Opin Urol. 2009;19:143-7.
11. Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer. 2008;113:2671-80.
12. Maturen KE, Nghiem HV, Caoili EM, Higgins EG, Wolf JS Jr, Wood DP Jr. Renal mass core biopsy: accuracy and impact on clinical management. AJR Am J Roentgenol. 2007;188:563-70.
13. Neuzillet Y, Lechevallier E, Andre M, Daniel L, Coulange C. Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses. J Urol. 2004;171:1802-5.
14. Wood BJ, Khan MA, McGovern F, Harisinghani M, Hahn PF, Mueller PR. Imaging guided biopsy of renal masses: indications, accuracy and impact on clinical management. J Urol. 1999;161:1470-4.
15. Pandharipande PV, Gervais DA, Mueller PR, Hur C, Gazelle GS. Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis. Radiology. 2008;248:169-78.
16. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1172-7.
17. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38.
18. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. http://www.cadth.ca/media/ pdf/186-EconomicGuidelines-e.pdf (2006). Accessed 8 Nov 2009.
19. Canadian Cancer Society's Steering Committee. Canadian cancer statistics, 2010. http://www.cancer.ca/Canada-wide/About%20cancer/Cancer%20statistics/ Canadian%20Cancer%20Statistics.aspx?sc-lang=en (2010). Accessed 3 Feb 2011.
20. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003;170(6 Pt 1):2217-20.
21. Thompson RH, Kurta JM, Kaag M, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol. 2009;181:2033-6.
22. Pahernik S, Ziegler S, Roos F, Melchior SW, Thuroff JW. Small renal tumors: correlation of clinical and pathological features with tumor size. J Urol. 2007;178:414-7.
23. Duchene DA, Lotan Y, Cadeddu JA, Sagalowsky AI, Koeneman KS. Histopathology of surgically managed renal tumors: analysis of a contemporary series. Urology. 2003;62:827-30.
24. Remzi M, Ozsoy M, Klingler HC, et al. Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol. 2006;176:896-9.
25. Schachter LR, Cookson MS, Chang SS, et al. Frequency of benign renal cortical tumors and histologic subtypes based on size in a contemporary series: what to tell our patients. J Endourol. 2007;21:819-23.
26. Shannon BA, Cohen RJ, de Bruto H, Davies RJ. The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses. J Urol. 2008;180:1257-61.
27. Volpe A, Mattar K, Finelli A, et al. Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. J Urol. 2008;180:2333-7.
28. Somani BK, Nabi G, Thorpe P, et al. Image-guided biopsy-diagnosed renal cell carcinoma: critical appraisal of technique and long-term follow-up. Eur Urol. 2007;51:1289-95.
29. Wang R, Wolf JS Jr, Wood DP Jr, Higgins EJ, Hafez KS. Accuracy of percutaneous core biopsy in management of small renal masses. Urology. 2009;73:586-90.
30. Matin SF, Ahrar K, Cadeddu JA, et al. Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol. 2006;176:1973-7.
31. Atwell TD, Farrell MA, Leibovich BC, et al. Percutaneous renal cryoablation: experience treating 115 tumors. J Urol. 2008;179:2136-40.
32. Derweesh IH, Malcolm JB, Diblasio CJ, et al. Single center comparison of laparoscopic cryoablation and CT-guided percutaneous cryoablation for renal tumors. J Endourol. 2008;22:2461-7.
33. Finley DS, Beck S, Box G, et al. Percutaneous and laparoscopic cryoablation of small renal masses. J Urol. 2008;180:492-8.
34. Georgiades CS, Hong K, Bizzell C, Geschwind JF, Rodriguez R. Safety and efficacy of CT-guided percutaneous cryoablation for renal cell carcinoma. J Vasc Interv Radiol. 2008;19:1302-10.
35. Hinshaw JL, Shadid AM, Nakada SY, Hedican SP, Winter TC 3rd, Lee FT Jr. Comparison of percutaneous and laparoscopic cryoablation for the treatment of solid renal masses. AJR Am J Roentgenol. 2008;191:1159-68.
36. Littrup PJ, Ahmed A, Aoun HD, et al. CT-guided percutaneous cryotherapy of renal masses. J Vasc Interv Radiol. 2007;18:383-92.
37. Malcolm JB, Berry TT, Williams MB, et al. Single center experience with percutaneous and laparoscopic cryoablation of small renal masses. J Endourol. 2009;23:907-11.
38. Mues AC, Okhunov Z, Haramis G, D'Agostino H, Shingleton BW, Landman J. Comparison of percutaneous and laparoscopic renal cryoablation for small (<3.0 cm) renal masses. J Endourol. 2010;24:1097-100.
39. Silverman SG, Tuncali K, van Sonnenberg E, et al. Renal tumors: MR imaging-guided percutaneous cryotherapy - initial experience in 23 patients. Radiology. 2005;236:716-24.
40. Hui GC, Tuncali K, Tatli S, Morrison PR, Silverman SG. Comparison of percutaneous and surgical approaches to renal tumor ablation: metaanalysis of effectiveness and complication rates. J Vasc Interv Radiol. 2008;19:1311-20.
41. Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology. 1995;197:589-97.
42. Wehle MJ, Thiel DD, Petrou SP, Young PR, Frank I, Karsteadt N. Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. Urology. 2004;64:49-52.
43. Sowery RD, Siemens DR. Growth characteristics of renal cortical tumors in patients managed by watchful waiting. Can J Urol. 2004;11:2407-10.
44. Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer. 2009;115:2844-52.
45. Abou Youssif T, Kassouf W, Steinberg J, Aprikian AG, Laplante MP, Tanguay S. Active surveillance for selected patients with renal masses: updated results with long-term follow-up. Cancer. 2007;110:1010-4.
46. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.
47. Remak E, Charbonneau C, Negrier S, Kim ST, Motzer RJ. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol. 2008;26:3995-4000.
48. Statistics Canada. Life expectancy at birth and at age 65 by sex and by geography. http://www.statcan.gc.ca/pub/84f0211x/2007000/t032-eng.htm (2007). Accessed 15 Oct 2010.
49. Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol. 2005;173:1889-92.
50. National Center for Health Statistics. United States life tables, 2006. http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58-21.pdf (2006). Accessed 21 Feb 2011.
51. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146:473-81.
52. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-90.
53. Statistics Canada. Complete life table, Canada, 2000 to 2002. http://www.statcan.gc.ca/pub/84-537-x/4064441-eng.htm (2002). Accessed 15 Oct 2010.
54. Ontario Ministry of Health and Long-Term Care. Schedule of benefits for physician services under the Health Insurance Act, 2009. http://www.health.gov. on.ca/english/providers/program/ohip/sob/physserv/physserv-mn.html (2009). Accessed 1 July 2010.